Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05791201 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | PHASE1 | ACTIVE NOT_RECRUITING | 7 | — | — | May 16, 2023 | Mar 12, 2027 | Jun 4, 2026 | 16 | United States, Canada +5 |
| Arm | Type | Description |
|---|---|---|
| VX-264 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-264 | DRUG | Allogeneic human stem cell-derived islets. |
Key Inclusion Criteria: Clinical history of T1D with greater than or equal to (\>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study Ke...